Information Provided By:
Fly News Breaks for February 14, 2020
DXCM
Feb 14, 2020 | 05:57 EDT
Stifel analyst Mathew Blackman raised his price target for DexCom to $300 from $250 saying the company's Q4 revenue exceeded pre-announced results, gross and operating margins came in above expectations, and first-time 2020 profitability guidance implies continued margin expansion despite heavier investment ahead. The company's "robust" 2020 outlook could prove conservative, adds Blackman, who admits he's running out of superlatives that adequately describe DexCom's "significant" revenue growth and profitability momentum. The analyst maintains a Buy rating on the shares.